Polymyositis (PM) and dermatomyositis (DM) are systemic autoimmune diseases of unknown etiology that primarily affect the skeletal muscle. Despite the improvement achieved in recent years with new therapeutic options, the prognosis remains poor, with high rates of morbidity and mortality. Conventional first-line treatment is based on glucocorticoids. However, their use in many patients requires long-term administration, which increases the probability of side effects developing. Thus, there is often the need to add immunosuppressive or immunomodulatory agents to improve the disease’s response to treatment and to reduce the longterm complications linked to glucocorticoid. Among the treatment options, the use of immunoglobulin, by both the intravenous (IVIg) and the subcutaneous (SCIg) route, is still under debate We describe here our experience with the use of SCIg in patients with PM and DM.
Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications / Gelardi, C; Paolini, L; Danieli, Maria Giovanna. - In: ISRAEL MEDICAL ASSOCIATION JOURNAL. - ISSN 1565-1088. - STAMPA. - 16:10(2014), pp. 646-647.
Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications.
DANIELI, Maria Giovanna
2014-01-01
Abstract
Polymyositis (PM) and dermatomyositis (DM) are systemic autoimmune diseases of unknown etiology that primarily affect the skeletal muscle. Despite the improvement achieved in recent years with new therapeutic options, the prognosis remains poor, with high rates of morbidity and mortality. Conventional first-line treatment is based on glucocorticoids. However, their use in many patients requires long-term administration, which increases the probability of side effects developing. Thus, there is often the need to add immunosuppressive or immunomodulatory agents to improve the disease’s response to treatment and to reduce the longterm complications linked to glucocorticoid. Among the treatment options, the use of immunoglobulin, by both the intravenous (IVIg) and the subcutaneous (SCIg) route, is still under debate We describe here our experience with the use of SCIg in patients with PM and DM.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.